This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
People suffering from COVID-19 could have several different SARS-CoV-2 variants hidden away from the immune system in different parts of the body, finds new research published in Nature Communications by an international research team. The study’s authors say that this may make complete clearance of the virus from the body of an infected person, by their own antibodies, or by therapeutic antibody treatments, much more difficult.
Annual Drug Patent Expirations for TEKTURNA+HCT Tekturna Hct is a drug marketed by Noden Pharma and is included in one NDA. It is available from one supplier. There are two…. The post New patent expiration for Noden Pharma drug TEKTURNA HCT appeared first on DrugPatentWatch - Make Better Decisions.
The Centers for Medicare & Medicaid Services (CMS) has recently released its 2022 data on enrollment in Medicare Part D prescription drug plans (PDPs). Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks.
Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central or peripheral nervous system. Millions of people are affected by these conditions across the globe, and with improved life expectancy in many parts of the world, it is likely that incidence will increase in the future.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Use of the drug verapamil to treat Type 1 diabetes continues to show benefits lasting at least two years, researchers report in the journal Nature Communications. Patients taking the oral blood pressure medication not only required less daily insulin two years after first diagnosis of the disease, but also showed evidence of surprising immunomodulatory benefits.
This chart shows the pharmaceutical companies with the most patents in Brazil. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Brazil? appeared first on DrugPatentWatch - Make Better Decisions.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
This chart shows the pharmaceutical companies with the most patents in Brazil. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Brazil? appeared first on DrugPatentWatch - Make Better Decisions.
Today’s guest post comes from Miranda Gill, Vice President of Network at CoverMyMeds. Miranda discusses how integrated technology solutions can be used at critical moments in the patient’s journey to increase access, affordability, and adherence to therapies. To learn more about CoverMyMeds’ prescription decision support tools for the entire care team, visit CoverMyMeds at HIMSS22.
Multiple Sclerosis Journal has published data from the ALITHIOS open-label extension study which provide a robust picture of the continuous safety data for Kesimpta, showing it was well tolerated in ~2000 patients with up to 3.5 years exposure with no new safety risks identified 1 Immunoglobulin G (IgG) levels remained stable in patients treated up to 3.5 years and mean immunoglobulin M (IgM) levels decreased yet remained above the lower limit of normal in most patients treated with Kesimpta 1 L
This chart shows the drugs with the most patents in United Kingdom. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical drugs have the most drug patents in United Kingdom? appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The Centers for Medicare & Medicaid Services (CMS) has recently released its 2022 data on enrollment in Medicare Part D prescription drug plans (PDPs). Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks.
In early 2019, no one could have predicted that a novel coronavirus would sweep around the globe and cause one of the most significant health crises of recent times. Fast-forward to today, and thousands of scientists have turned their attention to studying SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. This research pivot led to a torrent of scientific papers describing the structure and biology of the virus being published.
Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for prevention of RSV-associated lower respiratory tract illness in infants from birth up to six months of age by active immunization of pregnant women.
Annual Drug Patent Expirations for YUPELRI Yupelri is a drug marketed by Mylan Ireland Ltd and is included in one NDA. It is available from one supplier. There are fifteen…. The post New patent for Mylan Ireland drug YUPELRI appeared first on DrugPatentWatch - Make Better Decisions.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The World Health Organization (WHO) defines clinical trials as a type of research that studies new tests and treatments and evaluates their effects on human health outcomes (1). Clinical trials […]. The post Clinical Trial Approval Process in Australia appeared first on ProRelix Research.
For the first time in two years, we write from the confines of our office in downtown Philadelphia. While we loved the full-time “work from home” regime, we have fondly re-embraced the near-forgotten view from our 30 th -floor window, along with our Dancing Barney doll, our RBG action figure, and our solar-powered effigy of Queen Elizabeth II (she pivots her wrist in a perfect royal wave when she’s placed in the sun).
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced an initial donation of essential medicines to Ukraine. Roche vehemently condemns the violent invasion of the country. Roche is working diligently to support the country and people of Ukraine with medical products in accordance with Roche’s overall mission and announced today that we are donating 150,000 packages of Rocephin, a critical antibiotic used to treat the symptoms of many kinds of bacterial infections and listed on the World Health Orga
Annual Drug Patent Expirations for ZYNRELEF+KIT Zynrelef Kit is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Heron Theraps drug ZYNRELEF KIT appeared first on DrugPatentWatch - Make Better Decisions.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for LIVMARLI Livmarli is a drug marketed by Mirum and is included in one NDA. The generic ingredient in LIVMARLI is maralixibat chloride. Additional details are…. The post New patent for MIRUM drug LIVMARLI appeared first on DrugPatentWatch - Make Better Decisions.
Kelly Gast appointed as new Chief Financial Officer, effective April 1, 2022 / Frank Terhorst to lead new team combining Strategy with Sustainability & Public Affairs, effective March 1, 2022. Bayer today announced changes in the leadership team of its Crop Science division, with Kelly Gast assuming the position of Chief Financial Officer (CFO) from Michael A.
This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Annual Drug Patent Expirations for BYDUREON+PEN Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent expiration for Astrazeneca Ab drug BYDUREON PEN appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for BYDUREON Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are twenty-three patents…. The post New patent expiration for Astrazeneca Ab drug BYDUREON appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for BYDUREON+BCISE Bydureon Bcise is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are fifteen…. The post New patent expiration for Astrazeneca Ab drug BYDUREON BCISE appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for SAFYRAL Safyral is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from two suppliers. There are three patents…. The post New patent expiration for Bayer Hlthcare drug SAFYRAL appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for BEYAZ Beyaz is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from two suppliers. There are four patents…. The post New patent expiration for Bayer Hlthcare drug BEYAZ appeared first on DrugPatentWatch - Make Better Decisions.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
100 
Let's personalize your content